John C. Reed, M.D., Ph.D., New Editor-in-Chief of AACR’s Journal Molecular Cancer Therapeutics
New senior editorial team announced
PHILADELPHIA — The American Association for Cancer Research is pleased to announce that John C. Reed, M.D., Ph.D., chief executive officer, professor and Donald Bren chief executive chair at Sanford-Burnham Medical Research Institute, La Jolla, Calif., will be the new editor-in-chief of one of its seven major peer-reviewed journals, Molecular Cancer Therapeutics .
“I am very honored for the opportunity to lead the journal and build upon the success of the past decade,” said Reed, who will formally assume a five-year term as editor-in-chief today.
Molecular Cancer Therapeutics is a daily online and monthly print publication that provides a high-profile platform for reporting cancer research in the areas of experimental therapeutics, drug discovery and preclinical development. It was first published in November 2001 and has been consistently ranked in the top 25 percent of oncology journals with regard to Impact Factor.
“The American Association for Cancer Research is extremely proud to have such a prominent researcher as Dr. Reed take the helm of Molecular Cancer Therapeutics,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “We are sure that his in-depth knowledge of cancer therapeutics, his vision of strategic approaches to drug development and his tremendous experience in publishing hundreds of high-quality, peer-reviewed articles in the field will help us drive the journal forward to new heights.”
Reed’s scientific accomplishments have resulted in his authorship of more than 800 publications in cancer and biomedical science journals. He was recognized by the Institute for Scientific Information as the world’s most highly cited scientist for his research publications during the 1995-2005 decade in the fields of cell biology and general biomedicine. Around the same time, Thomson Scientific named him Doctor of the Decade.
Reed is an inventor with more than 90 patents and is the founder or co-founder of four biotechnology companies. His primary research interests are defining the fundamental mechanisms that regulate cellular life span and determining how these processes go awry in disease states such as cancer. Reed is a pioneer in devising new cancer therapeutic strategies based on targeting tumor cell survival mechanisms.
Reed received both his M.D. and Ph.D. from the University of Pennsylvania in Philadelphia in 1986. He then completed his residency in clinical pathology at the Hospital of the University of Pennsylvania, while at the same time undertaking postdoctoral research at the Wistar Institute, also in Philadelphia. After four years as an assistant professor at the University of Pennsylvania and assistant director of the laboratory of molecular diagnosis at the university’s hospital, Reed moved to Sanford-Burnham Medical Research Institute, where he has worked as a scientist and leader for more than 20 years, including serving as director of the institute’s National Cancer Institute-designated Cancer Center.
Reed succeeds Daniel D. Von Hoff, M.D., physician-in-chief and director of translational research at the Translational Genomics Research Institute (TGen), who was the journal’s founding editor-in-chief. Von Hoff helped refine the mission of Molecular Cancer Therapeutics over the past decade.
Reed has initially named the outstanding group of experts below, who will join the Molecular Cancer Therapeutics senior editorial team as deputy or senior editors. Additional senior members will be named, along with the editorial board, in the near future.
- Kenneth W. Bair, Ph.D., FORMA Therapeutics, Inc., Cambridge, Mass.
- Steven Grant, M.D., Virginia Commonwealth University, Richmond, Va.
- Stuart L. Schreiber, Ph.D., The Broad Institute of MIT and Harvard, Cambridge, Mass.
- Kapil N. Bhalla, M.D., University of Kansas Cancer Center, Westwood, Kan.
- Dennis A. Carson, M.D., University of California, San Diego, La Jolla, Calif.
- Leland W.K. Chung, Ph.D., Cedars-Sinai Medical Center, Los Angeles, Calif.
- Johann S. de Bono, Ph.D., Institute for Cancer Research, Sutton, England
- Carolyn Dive, Ph.D., University of Manchester, Manchester, England
- Tona M. Gilmer, Ph.D., GlaxoSmithKline, Research Triangle Park, N.C.
- Mark I. Greene, M.D., Ph.D., University of Pennsylvania, Philadelphia, Pa.
- Peter J. Houghton, Ph.D., Nationwide Children’s Hospital, Columbus, Ohio
- Catriona H.M. Jamieson, M.D., Ph.D., University of California, San Diego, Moores Cancer Center, La Jolla, Calif.
- Candace S. Johnson, Ph.D., Roswell Park Cancer Institute, Buffalo, N.Y.
- Ricky W. Johnstone, Ph.D., Peter MacCallum Cancer Center, Melbourne, Australia
- John S. Lazo, Ph.D., University of Virginia, Charlottesville, Va.
- Garth Powis, D.Phil., The University of Texas MD Anderson Cancer Center, Houston, Texas
- Michael G. Rosenblum, Ph.D., The University of Texas MD Anderson Cancer Center, Houston, Texas
- Stephen H. Safe, Ph.D., Texas A&M University, College Station, Texas